Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology

Persistent smoking after lung cancer has been the subject of medical, therapeutic and epidemiological publications for twenty years of research. Continued persistent smoking is all the more a problem for oncologists as there is evidence that smoking cessation, with lung cancer, gives therapeutic benefit. Quitting smoking can improve the response to treatments (chemotherapy, radiotherapy, surgery), quality of life and overall survival. However many patients refuse adhesion to tobacco cessation. Daily practice leads us to the hypothesis that adhesion differences aren't related to the denial of medical information, nor to resignation or to nicotine dependence. Patients who continue smoking seem to face a form of impossibility to wean. Cigarette seems to be felt as a part of their body in their narration and description of their body image.

Study Overview

• Status: Completed
• Conditions: Smoking Cessation and Lung Cancer
• Intervention / Treatment: Behavioral: Research interviews; Behavioral: Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R); Behavioral: Projective methods (Thematic apperception Test, Rorschach); Behavioral: Carbon monoxide test

• Study Type: Observational
• Enrollment (Actual): 50

Contacts and Locations

Study Locations

• France
  • Strasbourg, France, 67091
    • Nouvel Hôpital Civil, Service de pneumologie, Unité de cancérologie thoracique, Hôpitaux Universitaires de Strasbourg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients will be recruited in the pneumology ward of Strasbourg University Hospital, precisely in hospitalization units involved in cancer care (Units 1404,1403,1202,2099)

Description

Inclusion Criteria:

• Men and women aged 18 years or older
• Patient affiliated to a social security system
• Patient who has signed and dated informed consent, written before all procedures related to the study
• Patient who has received the results of the previous mandatory medical examination
• Patient who has been diagnosed with lung cancer, regardless of the histological type of the cancer
• Patient who maintains an active smoking at the time of inclusion
• Patient who has smoked at least one cigarette in the previous year of inclusion
• Patient who is being treated for lung cancer (surgery, chemotherapy, radiotherapy) and not another form of cancer
• Tobacco consumer's only by smoke inhalation
• Tobacco consumer's or tobacco associated with cannabis

Exclusion Criteria:

• Major patient under guardianship or curatorship or maintenance of justice
• Patient deprived of his liberty or in an emergency situation
• Patient with a Performance Statut(OMS) higher than 2 and/or with a psychiatric disorder like " schizophrenia and other psychotic disorders " (DSM IV)
• A palliative care patient
• Patient who began smoking during his diagnostic examination or after the diagnosis of cancer
• A pregnant or breastfeeding woman
• Patient in an exclusion period

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Smokers with lung cancer	Behavioral: Research interviews; Behavioral: Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R); Behavioral: Projective methods (Thematic apperception Test, Rorschach); Behavioral: Carbon monoxide test

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite indicator variable indicating the presence or absence of disturbance in one or more of the parameters evaluated: object relations, body, subject's choice.	The results will be obtained: From the results of each test, each has indeed a standardized rating scale; By analysing the content of the speech of the patient previously noted during the various interviews The investigator will classify each subject in "disturbance" or not for each of the three parameters. The presence of at least one disturbance gives the "yes" value in the indicator variable, "no" in the absence of the three disturbances.	2 months after inclusion
Composite indicator variable indicating the presence or absence of disturbance in one or more of the parameters evaluated: object relations, body, subject's choice.	The results will be obtained: From the results of each test, each has indeed a standardized rating scale; By analysing the content of the speech of the patient previously noted during the various interviews The investigator will classify each subject in "disturbance" or not for each of the three parameters. The presence of at least one disturbance gives the "yes" value in the indicator variable, "no" in the absence of the three disturbances.	4 months after inclusion

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France
• Investigators: Principal Investigator: Jonathan GRAFFI, Hôpitaux Universitaires de Strasbourg

Study record dates

Study Major Dates

• Study Start: December 1, 2013
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: September 20, 2013
• First Submitted That Met QC Criteria: September 27, 2013
• First Posted (Estimate): October 7, 2013

Study Record Updates

• Last Update Posted (Estimate): June 9, 2016
• Last Update Submitted That Met QC Criteria: June 8, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antimetabolites; Gasotransmitters; Carbon Monoxide
• Other Study ID Numbers: 5579